Sanford C. Bernstein set a €90.00 ($104.65) target price on Bayer (FRA:BAYN) in a research report released on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other equities analysts have also recently commented on BAYN. Nord/LB reaffirmed a neutral rating on shares of Bayerische Motoren Werke in a research report on Tuesday, June 4th. Baader Bank set a €123.00 ($143.02) price objective on shares of Bayer and gave the stock a buy rating in a research report on Thursday, June 27th. Kepler Capital Markets set a €70.00 ($81.40) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Thursday, June 27th. Warburg Research set a €17.00 ($19.77) price objective on shares of Leoni and gave the stock a neutral rating in a research report on Wednesday, May 15th. Finally, Deutsche Bank reduced their price objective on shares of Xilinx from $125.00 to $120.00 and set a hold rating for the company in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of €80.67 ($93.81).
BAYN stock opened at €59.55 ($69.24) on Thursday. The stock’s fifty day moving average is €56.65. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Return On Assets
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.